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BENZODIAZEPINES IN PSYCHOTIC STATES 
JAMBUR ANANTH, OLUSEGUN SOLANO 
SUMMARY 
Benzodiazepines are primarily used for the treatment of generalized anxiety disorder, insomnia and status 
epilepticus. These drugs can also be useful in hyperaroused states, catatonic stupor, manic episodes, and akathisia. 
This paper will review indications for their use in various psychotic conditions. 
INTRODUCTION 
Benzodiazepines are the most prescribed drugs for the 
past two decades. They act by binding to a specific recep-
tor complex that includes a GABA receptor (Bowery et al, 
1984; Gallager, 1978). Functional synergy exists between 
benzodiazepine and GABA receptors (Iversen, 1983; 
Richards & Moeler, 1984; Haefely et al, 1983), and in the 
central nervous system, benzodiazepines inhibit neuronal 
firing (Laurant et al, 1983). It appears that ben-
zodiazepine/GABA receptor complexes in different areas 
of the central nervous system mediate their anxiolytic, 
anticonvulsant, muscle relaxant and hypnotic effects 
(Neihoff & Kuhar, 1983). 
In addition to the above mentioned indications, ben-
zodiazepines are also used to treat acute psychotic states 
with the possibility of rapid amelioration of agitated and 
disruptive behavior. In combination with neuroleptics, 
they may help in lowering the neuroleptic dosage arid 
decrease the occurrence of serious side effects. In this 
review, the rationale, clinical indications and guidelines 
for the use of benzodiazepines in the treatment of 
psychotic states and related disorders will be explored. 
CLINICAL APPLICATION IN PSYCHOTIC 
STATES 
I. Catatonic Stupor 
Catatonia is a syndrome characterized by varying 
degrees of mutism and akinesia with a clear state of 
consciousness (Morrison, 1978). Various psychiatric, 
neurologic, metabolic or toxic disorders may present with 
catatonic features (Stoudemire, 1982; Fricchione, 1985). 
Neuroleptic administration, even though beneficial in a 
majority of cases, may worsen catatonia in some instances. 
Hence alternate and effective treatment is needed. 
Biochemically, benzodiazepines increase GABAergic 
transmission, decrease dopamine release and enhance 
motor activity. Similarly, Mucimol, a GABA agonist in-
creases motor activity, aggression, and food intake in rats 
(Fricchione, 1985; Garbutt & Van Kammen, 1983) which 
can be blocked by haioperidol. These findings suggest 
both psychogenic and haloperidol induced catatonia may 
respond to benzodiazepines. 
Recently there are a number of case reports which 
suggest that catatonicstupor(Salam et al, 1987; Greenfeld 
et al, 1987; McEvoy & Lohr, 1984; Casey, 1987; Green-
berg et al, 1986; Harris & Menza, 1989; Heuser & Benkert, 
1986; Ripley &Millson, 1988; Vinogradov &Reiss, 1986; 
Walter-Ryan, 1985; Wetzel, 1987) neuroleptic induced 
catatonia (Fricchione et al, 1983), and organic stupor 
(Sheline & Miller, 1986) responds dramatically, some 
times as quickly as one hour after the administration of 
benzodiazepines. Most often lorazepam and occasionally 
other preparations such as diazepam (McEvoy & Lohr, 
1984; Sheline & Miller, 1986) and clonazepam (Martenyi 
et al, 1986) have been employed. In a literature review, 
Salam and Kilzeih (1988) emphasized that 1 to 4 mg of 
lorazepam was beneficial in 22 out of 24 catatonic patients. 
Rosenbush et al (1990) described that 12of the 15 episodes 
of catatonic stupor encountered in one year, including 
stupor with affective disorder, drug induced psychosis, 
atypical psychosis and organic conditions improved with 
lorazepam. As the drug effect wears off the patient may 
revert to stupor again (Wetzel et al, 1987). 
The current data indicate that benzodiazepines are 
useful in alleviating stupor caused by divergent condi-
tions. This effect is only symptomatic and nonspecific. 
Therefore, treatment of the primary disorder has to be 
aggressively sought to prevent reversion to stupor. 
II. Hyperaroused and Agitated States. 
The need for medication to provide rapid control of 
agitated and potentially violent patients in the emergency 
settings cannot be overemphasized. Rapid tranquilization 
with neuroleptics, an important tool in the management of 
such patients, may induce severe side effects. Further-
more, neuroleptic induced akathisia may mimican exacer-
bation of excitatory symptoms and akinetic mutism may 
be mistaken for a psychogenic catatonic state leading to 
administration of more medication with disastrous results. 
Benzodiazepines have a distinct advantage in treating 
acute psychotic patients who are unwilling or unable to 
provide a proper and reliable history thereby posing a 
problem in making a proper diagnosis. 
Intramuscular injection of 2.5 mg of midazolam (Men-
doza et al, 1987) and 1 to 2 mg of lorazepam (Dubin, 1987) 
were found to be beneficial within two to four hours in 
patients exhibiting acute hyper-arousal and violent be-
havior, respectively. While antipsychotic medications still 
remain the preferred method of achieving rapid tran-
quilization in patients with a verified diagnosis of 
schizophrenia, poor self care, malnutrition and usage of 
street drugs and alcohol in these patients make them 
susceptible to side effects. Therefore, addition of ben-
zodiazepines might serve to lower the dosage of neurolep-
tics and thereby decrease side effects (Dubin, 1987; Bick 
& Hannah, 1986). 
Retrospective chart reviews have revealed that a 
decrease in neuroleptic dose to 47 percent (Arana et al, 
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1986; Busch et al, 1989) and 50 percent (Salzman et al, 
1986) of the original dose occurs in patients receiving the 
combinaion of benzodiazepines and neuroleptics. In ad-
dition, the combination decreased restraints (Busch et al, 
1989) and provided a more rapid therapeutic response 
(Garza-Trevino et al, 1989). Lorazepam alone has been 
found to be as effective as haloperidol in psychotic agita-
tion (Arana et al, 1986). 
It is our hypothesis that agitated and violent patients 
have two kinds of psychopathology, an anxiety-arousal 
related disruption and an autonomous psychosis. Clinical-
ly, it is not possible to delineate these two groups. Actual-
ly, disturbed patients may manifest arousal related 
disruption as a result of an exacerbation of psychosis and 
conversely, arousal related disruptions may in turn en-
hance the preexisting autonomous thought disorder. Ben-
zodiazepine administration to these patients improves 
arousal related disruptions, while theireffea on psychosis 
is uncertain. Furthermore, the onset of action of neurolep-
tics and benzodiazepines are different. The latter improves 
the arousal related psychopathology as early as one to two 
hours after administration and the former improves 
psychosis as late as a few days to weeks after administra-
tion. In support of this hypothesis, are the findings of 
Lerner and coworkers (1979) who noted that ben-
zodiazepines can improve symptoms within four hours 
and neuroleptics after 24 hours in acute psychotic patients. 
It is likely that both drugs improve different groups of 
symptoms. Our study (Mendoza et al, 1987) indicates that 
hyper-aroused patients improve within one to four hours. 
If a patient does not improve in four hours, it is unlikely 
that he has arousal related symptoms and further use of 
benzodiazepines may not be of much use. Intramuscular 
medication is needed only in patients who refuse oral 
medication. 
III. Acute and chronic schizophrenic states 
In general, benzodiazepines are not as effective as 
antipsychotic drugs in treating psychotic disorders, but 
they may be very useful especially during the initial phase 
of psychotic illness. Cohen et al (1987) reported that more 
than 2mg of lorazepam per day when used in combination 
with moderate doses of neuroleptic leads to greater im-
provement in the first four days of acute exacerbation of 
schizophrenia in comparison to those treated with 
neuroleptics alone. There are anecdotal reports of im-
provement of acute schizophrenia with chlorazepate 
(Joseph, 1987), clonazepam (Raines & Greenspan, 1987) 
and diazepam. Of the nine studies comparing the effect of 
neuroleptics with that of neuroleptic- benzodiazepine 
combination, four reported positive (Guz et al, 1972; 
Kellener et al, 1975; Lingjaerde, 1979; Lingjaerde et al, 
1982) while the other five reported negatively (Hanlon et 
al, 1969 & 1970, Holden et al, 1968; Karson et al, 1982; 
Michaux et al, 1969). These discrepancies may wel 1 reflect 
differences in the population studied. The fact that more 
recent studies reveal positive results indicate the pos-
sibility that the earlier studies might have been conducted 
on chronic institutionalized patients who were unable to 
report improvement or had very little anxiety-arousal re-
lated symptoms, thus making them inaccessible to ben-
zodiazepines. Kirkpatrick (1989), on the assumption that 
early symptoms of schizophrenic relapse are related xo 
environmental stress, treated such patients with only 
diazepam and reported positive results. This area needs to 
be further evaluated. 
Benzodiazepines have been employed in the treatment 
of neuroleptic resistant chronic schizophrenic patients 
having hallucinations, delusions, and paranoid ideation. 
The rationale is that, in animal studies, diazepam in high 
doses acts like the neuroleptic clozapine and inhibits 
central dopaminergic systems (Bunney & Aghajanian, 
1974). As benzodiazepines areGABAergic, they may also 
alleviate postulated GABA deficiency in schizophrenia 
(Tallman et al, 1980; Van Kammen, 1979). Two uncon-
trolled studies with 18 patients have reported that 
diazepam alone improved schizophrenic psychosis 
(Nesteros et al, 1982; Beckman & Haas, 1980). Contrary 
to these, Jimroerson et al (1982) treated five patients with 
diazepam without any significant clinical effect. While the 
use of benzodiazepines as the sol e medication has not been 
proven to be effective, Estazolam, a triazolo ben-
zodiazepine has been reported to be useful in 
schizophrenic patients, particularly in chronic hal-
lucinatory psychosis (Astrup & Vatten, 1984). Currently, 
long term, double blind and controlled studies are needed 
to establish benzodiazepines in the treatment of chronic 
schizophrenic states and it may not be wise to use these as 
the sole medication in treating schizophrenic patients. 
IV. Negative Symptoms 
The relatively large number of treatment resistant 
schizophrenic patients with negative symptoms have 
prompted efforts to augment the therapeutic effects of 
conventional neuroleptics. To this end, benzodiazepines 
have been tries as adjuncts in the treatment of 
schizophrenia (Wolkowitz et al, 1986; Csernansky et al, 
1984 & 1988). Wolkowitz et al (1988) noted that in 12 
hospitalized schizophrenic patients meeting the RDC 
criteria and initially treated with fluphenazine 
hydrochloride for at least two weeks, the addition of 
alprazolam resulted in significant improvement in 
psychosis, notably positive symptoms. A nonsignificant 
decrease in negative symptoms in patients who showed an 
overall favorable response was also observed. 
Those patients who were more psychotic and more 
anxious during fluphenazine therapy than before showed 
the greatest improvement when alprazolam was added. 
However, the improvement observed during the second 
two weeks could be due to neuroleptics alone rather than 
the combination or due to the reduction of subclinical 
akathisia or other extrapyramidal symptoms. Csernansky 
et al (1984) in a double blind comparison of alprazolam, 
diazepam, and placebo concluded that alprazolam had no 
significant effect on negative symptoms of schizophrenia. 
The limitation of tl.e study was the degree of compliance 
to therapy of the exclusive outpatient population in their 
sample. To date, there are only three studies with a small 
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number of patients. The benefit reported can be due to a 
diminution of anxiety, depression, extrapyramidal 
symptoms or mild disinhibition. A careful analysis of the 
above mentioned variables in patients receiving ben-
zodiazepines, specifically alprazolam, is necessary to un-
derstand their clinical effects on negative symptoms. 
V. Mania 
Benzodiazepines have been administered to manic 
patients because of their relatively benign side effect 
profile associated with possible therapeutic efficacy. 
Lenox et al (1986) found that lorazepam administration to 
acute manic patients during the initial phases of lithium 
therapy produced sedation as well ascontrol of excitability 
and psychomotor activity to a degree that patients were 
manageable within the first two days of treatment. 
Psychotic symptoms on the other hand, improved within 
five to ten days, during which time plasma lithium levels 
ranged between 0.4 and 1.0 mEq/L. Peak lorazepam 
dosage averaged about 20 mg a day and the most sig-
nificant side effect was mild to moderate ataxia during the 
early phase of treatment. 
Clonazepam has been reported to have a specific anti-
manic property. This effect may be due to the potentiation 
of 5HT synthesis (Browne, 1978; Jenner et al, 1975) in 
addition to its well established GABAergic effect. As 
synthesis of 5HT has been hypothesized to be low in manic 
patients (Murphy et al, 1974 & 1978), clonazepam ad-
ministration may correct this deficiency (Schildkraut, 
1974; Wise et al, 1972) with a resultant antimanic effect. 
Chouinard (1985,1987a & 1987b) found that clonazepam 
was effective in the treatment of mania with a number of 
distinct advantages. He concluded from his study of 12 
acutely manic patients that clonazepam was more effective 
and faster acting than lithium in the first few days of 
therapy and there was a decreased need for neuroleptics 
which in turn diminished extrapyramidal side effects. He% 
therefore, suggested that 1 mg of clonazepam was 
equivalent to 2.5 mg of haloperidol. Even complicated 
(Victor et al, 1984), atypical (Pande, 1988), rapid cycling 
(Freinhar & Alvarez, 1985) or mixed (Adler, 1986) manic 
states have been reported to respond to clonazepam. 
The efficacy of clonazepam as a prophylactic agent has 
been investigated. In a retrospective study (Sachs et al, 
1990) of 20 patients, 13 were receiving lithium and an 
adjunctive neuroleptic and six were receiving lithium and 
clonazepam combinations. In the clonazepam group, an 
average of 2.2 cycles during the year preceding 
clonazepam was decreased to 0.94 cycles during the year 
on clonazepam. As the assignment was not random, the 
results are inconclusive. On the other hand, Aronson et al 
(1989) noted their patients became worse when they were 
switched from neuroleptic to clonazepam. There was a 
recurrence of affective episodes in all five patients within 
12 weeks. Hence, the specificity of clonazepam in acute 
mania appears promising, at least in the first week prior to 
the onset of action of lithium. Definitive conclusions can 
be derived following well designed, placebo controlled 
prospective studies. Sufficient evidence regarding its 
prophylactic action in bipolar disorders is not yet avail-
able. 
VI. Tardive Dyskinesia 
Tardive dyskinesia is associated with the long term 
administration of neuroleptics (Jeste et al, 1976; Jus et al, 
1976; Simpson et al, 1981; De Veaugh-Geiss, 1982; Han-
Ion et al, 1969, Holden et al, 1968; Michaux et al, 1966; 
Kirkpatrick, 1989). As the pathophysiology of this condi-
tion isstill elusive, treatment of this condition has not been 
rewarding (Ananth, 1982; Gerlach et al, 1974). Ben-
zodiazepines have been reported to be beneficial in the 
treatment of this condition (Goodwin-Austin & Clark, 
1971; Jus et al, 1974; O'Flanagan, 1975; Singh, 1976; 
Jeste & Wyatt, 1979 & 1982). GABAergic action of 
benzodiazepines is implicated in this therapeutic action 
(Johnson, 1976; Singh et al, 1980). Diazepam (Singh, 
1976) and clonazepam (O'Flanagan, 1975; Thaker et al, 
1990) have been found to be beneficial in neuroleptic 
induced and tricyclic induced (Deckret et al, 1977; Fann 
et al, 1976; Sedivec et al, 1970; Woogen et al, 1981) 
tardive dyskinesia, respectively. However, tricyclic in-
duced tardive dyskinesia is infrequent and may constitute 
a different subgroup. In contrast, i n one study (Rosenbaum 
& De la Fluente, 1979), diazepam aggravated tardive 
dyskinesia while in another, clonazepam was found to be 
no belter than phenobarbital in reducing tardive dyskinesia 
(Bobruff et al, 1981). Therefore, the therapeutic effects of 
benzodiazepines in tardive dyskinesia, if any, may simply 
be due to a nonspeci fie sedative effect. With the available 
evidence, it appears that benzodiazepines may not have 
any specific effect on tardive dyskinesia. 
VII.Akathisia 
Akathisia, an extrapyramidal side effect (Barels et al, 
1981; Braude et al, 1983; Delay & Deniker, 1968; 
Marsden & Jenner, 1980), may occur in twenty percent of 
neuroleptic treated patients. This condition is difficult to 
diagnose (Raskin, 1972; Donlon, 1973). because of its 
subtle manifestation and resemblance to other syndromes. 
The inner disquiet, anxiety, restlessness and the subjective 
need or desire to move exhibited by these patients can be 
mistaken for exacerbation of psychosis leading to the 
inadvertent increase in the dose of antipsychotics; conse-
quently, the patients' condition may worsen. As a side 
effect, it is trie most frequently cited reason for stopping 
neuroleptic medication by the patient (Van Putten, 1974). 
Discontinuation of the drug or a reduction of its dosage, 
administration of anticholinergics and antihistamines do 
not always provide prompt relief. Therefore, alternative 
treatments including the use of benzodiazepines are being 
explored. Diazepam was reported to be effective within 
three days in 13 akathisic patients (Donlon, 1973). Gagrat 
et al (1975) indicated that intravenous diazepam was as 
effective as anticholinergic drugs. Even dystonia as-
sociated with akathisia, previously unresponsive to stand-
ard treatment, improved with diazepam administration 
(Director & Munitz, 1982). Kutcher et al (1987) reported 
an open trial of clonazepam in 10 psychotic patients who 
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had incamplete relief of their akathisia with benztropine; 
when clonazepam was used as an adjunct, akathisia 
reduced significantly. Bartels et al (1987) indicated that 
complete remission occurred in nine and partial remission 
in the remaining five akathisic patients treated with 
lorazepam. On the other hand, Braude et al (1981) found 
that benzodiazepines did not produce any significant im-
provement. 
Akathisia is proposed to be due to supersensitivity of 
the noradrenergic neurons in the supraspinal and spinal 
regions (Barels et al, 1981). GABAergic stimulation 
produced by benzodiazepines, counterbalancing the 
noradrenergic overactivity as well as their anxiolytic ef-
fects, may be beneficial. As they are safe, they are the 
drugs of choice in patients who are unable to take an-
ticholinergicdrugs. 
DISADVANTAGES OF BENZODIAZEPINE 
THERAPY 
High dose therapy in acutely ill patients can cause 
sedation, memory disorders, disinhibition, ataxia and 
respiratory depression. Behavioral disinhibition is par-
ticularly a serious problem, as this side effect may mimic 
an exacerbation of psychosis. This has been noted with 
clonazepam (Karson et al, 1982), alprazolam (Faucett et 
al, 1987; Feighner et al, 1984; Gardner & Cowdry, 1985; 
Rosenbaum et al, 1984) and other benzodiazepi ne prepara-
tions as well. Ataxia may lead to fall and fractures in 
elderly. Excessive use in the hope of achieving a quick 
response may produce benzodiazepine toxicity. 
Respiratory depression can occur when combined with 
other central nervous system depressants. With long term 
use, dependence, sexual side effects, mania (Bacher et al, 
1986) as well as depression have been reported. 
CONCLUSION 
While neuroleptics remain the cornerstone of treatment 
of psychotic disorders, especially schizophrenia, their 
limitations have become apparent after many years of 
experience with their use. Basically, they do not helpevery 
patient and they have a lag period before improvement 
occurs. In addition to these variables, an acute psychotic 
process poses problems of a different dimension. The 
acute patient needs immediate relief to protect him from 
danger, which the neuroleptic cannot provide. An acutely 
ill patient may have problems of exhaustion, malnutrition, 
as well as other medical illnesses all of which predispose 
the patient to risks if neuroleptized. The psychopathology 
itself may be hyper-arousal related disruption, for which 
neuroleptic treatment may be improper. 
The need for immediate improvement without major 
side effects has prompted the investigation of alternatives 
to neuroleptics in acute psychosis. Of all the alternatives 
that have been tried, benzodiazepines seem to be the safest 
and the most effective. They have been proven to effective 
in both catatonic stupor and excitement. However, their 
role in the treatment of chronicschizophrenicstates as well 
as tardive dyskinesia has been disappointing. Even the 
limited use of benzodiazepines in such areas as hyper-
arousal states fill a much needed vacuum, with the added 
advantage of proven safety. When the drug is given in 
acute states, the patient should be observed for four hours. 
If no response occurs, this medication should be discon-
tinued. The rationale is that arousal related disruptions are 
immediately responsive to benzodiazepines and those that 
do not respond within this time period may not have 
arousal related psychopathology and hence, not accessible 
to benzodiazepine treatment. Further research in this area 
will be of interest to delineate the different 
psycho pathologies. 
While the traditional doses of benzodiazepines (when 
used as the sole agents) have not been noted to be consis-
tently useful in the treatment of psychosis, there has been 
some suggestion in the literature that higher doses might 
be effective (Lingjaerde, 1991). The recent ben-
zodiazepines, without significant sedation, may provide 
definitive answers regarding usefulness in higher doses in 
the treatment of schizophrenia. 
The authors wish to thank Mary Lou Galano for her 
secretarial assistance. 
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